In a significant development in the fight against lung cancer, doctors have initiated the world’s first mRNA lung cancer vaccine trials in patients across seven countries. This pioneering jab, known as BNT116 and developed by BioNTech, has the potential to revolutionise the treatment of non-small cell lung cancer (NSCLC), the most prevalent form of the disease.
Lung cancer remains the leading cause of cancer-related deaths worldwide, claiming approximately 1.8 million lives annually. Patients with advanced stages of the disease, where tumours have metastasised, face particularly dismal survival rates. The BNT116 vaccine aims to address this dire situation by harnessing the power of mRNA technology to instruct the body to seek out and destroy cancer cells while preventing their recurrence.
The phase 1 clinical trial, marking the first human study of BNT116, has been launched across 34 research sites in the United Kingdom, United States, Germany, Hungary, Poland, Spain, and Turkey. The UK boasts six sites, situated in England and Wales, with the first UK patient receiving their initial dose on Tuesday. The trial will enrol around 130 patients, with approximately 20 from the UK, spanning from early-stage cases prior to surgery or radiotherapy to late-stage or recurrent cancer. Participants will receive the vaccine alongside immunotherapy.
The jab employs messenger RNA (mRNA), akin to the technology used in Covid-19 vaccines, to present the immune system with tumour markers specific to NSCLC. This primes the body to target cancer cells expressing these markers while leaving healthy cells unharmed, offering a more targeted approach compared to chemotherapy.
Prof Siow Ming Lee, a consultant medical oncologist at University College London hospitals NHS foundation trust (UCLH), which spearheads the UK trial, expressed enthusiasm for this new era of mRNA-based immunotherapy clinical trials in lung cancer treatment. He emphasised the simplicity of delivery and the ability to select specific antigens in cancer cells for targeted treatment, hailing this technology as the next significant phase in cancer care.
Janusz Racz, a 67-year-old scientist from London specialising in AI, was the first person in the UK to receive the vaccine. Diagnosed in May, Racz underwent chemotherapy and radiotherapy before participating in the trial. He expressed hope that this new methodology, unavailable to other patients, could help him overcome cancer while contributing to the proof of concept for this innovative approach, ultimately benefiting countless others worldwide.
The trial aims to enhance survival rates by preventing cancer recurrence, a common challenge for lung cancer patients even after surgery and radiation. With the potential to become the standard of care worldwide, this mRNA vaccine, in combination with immunotherapy, could provide the extra boost needed to save numerous lives.
As the trial progresses through phases 2 and 3, the medical community eagerly anticipates the results, hoping to usher in a new era of groundbreaking therapies for lung cancer patients. The launch of this trial marks a significant step forward in the fight against this devastating disease, offering renewed hope for improved outcomes and survival rates.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.